

## References

- 7 Things You Need to Know about Edible Cannabis. Canadian Centre on Substance Use and Addiction. <https://www.ccsa.ca/sites/default/files/2019-06/CCSA-7-Things-About-Edible-Cannabis-2019-en.pdf>. Published 2019. Accessed December 16, 2021.
- About cannabis. Government of Canada. <https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/about.html#a1>. Updated October 17, 2018. Accessed August 17, 2021.
- Access to Cannabis for Medical Purposes Regulations – Daily Amount Fact Sheet (Dosage). Government of Canada. <https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/information-medical-practitioners/cannabis-medical-purposes-regulations-daily-amount-fact-sheet-dosage.html>. Revised August 19, 2016. Accessed November 22, 2021.
- Access to Cannabis for Medical Purposes: What Every Nurse Should Know. Canadian Nurses Protective Society. <https://cnps.ca/article/access-to-cannabis-for-medical-purposes-what-every-nurse-should-know/>. Published October 2018.
- Alberta Cannabis: Alberta's Legal, Recreational Online Cannabis Store. <https://albertacannabis.org/>. Published 2020. [NOTE: "As of March 8, 2022, AlbertaCannabis.org is no longer offering online sales of cannabis products."]
- Allan GM, Finley CR, Ton J, et al. Systematic review of systematic reviews for medical cannabinoids: Pain, nausea and vomiting, spasticity, and harms. *Can Fam Physician*. 2018;64(2):e78-e94. <https://pubmed.ncbi.nlm.nih.gov/29449262/>.
- Allan GM, Ramji J, Perry D, et al. Simplified guideline for prescribing medical cannabinoids in primary care. *Can Fam Physician*. 2018;64(2):111-120. <https://pubmed.ncbi.nlm.nih.gov/29449241/>.
- Andre CM, Hausman JF, Guerriero G. Cannabis sativa: The plant of the thousand and one molecules. *Front. in Plant Sci*. 2016;7. <https://doi.org/10.3389/fpls.2016.00019>.
- Andreae MH, Carter GM, Shaparin N, et al. Inhaled cannabis for chronic neuropathic pain: A meta-analysis of individual patient data. *J Pain*. 2015;16(12):1221-1232. <https://doi.org/10.1016/j.jpain.2015.07.009>.
- Antoniou T, Bodkin J, Ho JM-W. Drug interactions with cannabinoids. *CMAJ*. 2020;192(9):E206. <https://doi.org/10.1503/cmaj.191097>.
- Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. Antioxidative and anti-inflammatory properties of cannabidiol. *Antioxidants*. 2020;9(1):21. <https://doi.org/10.3390/antiox9010021>.
- Authorized cannabis retailers in the provinces and territories. Government of Canada. <https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/laws-regulations/provinces-territories.html>. Revised March 9, 2022.
- Bahji A, Meyyappan AC, Hawken ER. Cannabinoids for the neuropsychiatric symptoms of dementia: A systematic review and meta-analysis. *Can J Psychiatry*. Published online December 13, 2019. <https://doi.org/10.1177/0706743719892717>.
- Balneaves LG, Alraja A, Ziemianski D, Mccuaig F, Ware M. A national needs assessment of Canadian nurse practitioners regarding cannabis for therapeutic purposes. *Cannabis and Cannabinoid Res*. 2018;3(1):66-73. <https://doi.org/10.1089/can.2018.0002>.
- Barriers to Access for Canadians who use Cannabis for Medical Purposes. Canadian AIDS Society. <https://www.cdn aids.ca/barriers-to-access-for-canadians-who-use-cannabis-for-medical-purposes/>. Published May 16, 2014.
- Bashford J, Flett R, Copeland J. The Cannabis Use Problems Identification Test (CUPIT): development, reliability, concurrent and predictive validity among adolescents and adults. *Addiction*. 2010;105(4):615-625. <https://doi.org/10.1111/j.1360-0443.2009.02859.x>.
- BC Cannabis Stores. BC Cannabis Stores. Accessed October 22, 2021. <https://www.bccannabisstores.com/>.
- Be Wise. Cannabis and Older Adults. Active Aging Canada. 2021. <https://www.activeagingcanada.ca/assets/pdf/participants/projects/cannabis/AAC-Cannabis-and-Older-Adults-HR.pdf>. Accessed August 17, 2021.
- Behavioural Supports Ontario. Cannabis and Older Adults: Know the Facts! [https://brainxchange.ca/Public/BSO/Files/Substance-Use/Cannabis-Older-Adults-Know-the-Facts\\_print\\_only\\_Fl.aspx](https://brainxchange.ca/Public/BSO/Files/Substance-Use/Cannabis-Older-Adults-Know-the-Facts_print_only_Fl.aspx). Accessed October 25, 2021.
- Belle-Isle L, Walsh Z, Callaway R, et al. Barriers to access for Canadians who use cannabis for therapeutic purposes. *Int J Drug Policy*. 2014;25(4):691-699. <https://doi.org/10.1016/j.drugpo.2014.02.009>.
- Bennett C, Osburn L, Osburn J. *Green Gold The Tree of Life: Marijuana in Magic & Religion*. Frazier Park, CA: Access Unlimited, c1995. p. 267.
- Bertram JR, Porath A, Seitz D, et al. Canadian guidelines on cannabis use disorder among older adults. *Can Geriatr J*. 2020;23(1):135-142. <https://doi.org/10.5770/cgj.23.424>.
- Black N, Stockings E, Campbell G, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. *The Lancet Psychiatry*. 2019;6(12):995-1010. [https://doi.org/10.1016/s2215-0366\(19\)30401-8](https://doi.org/10.1016/s2215-0366(19)30401-8).
- Bobitt J, Qualls SH, Schuchman M. et al. Qualitative analysis of cannabis use among older adults in Colorado. *Drugs Aging*. 2019;36:655-666. <https://doi.org/10.1007/s40266-019-00665-w>.
- Bosnjak Kuharic D, Markovic D, Brkovic T, et al. Cannabinoids for the treatment of dementia. *Cochrane Database Syst Rev*. 2021;9(9):CD012820. <https://doi.org/10.1002/14651858.CD012820.pub2>.
- Brenneisen R, Egli A, Elshohly MA, Henn V, Spiess Y. The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. *Int J Clin Pharmacol Ther*. 1996;34(10):446-452. <https://pubmed.ncbi.nlm.nih.gov/8897084/#:~:text=Oral%20and%20rectal%20THC%20reduced,formulation%20was%2025%2D50%25>.
- Briscoe J, Casarett D. Medical marijuana use in older adults. *J Am Geriatr Soc*. 2018;66(5):859-863. <https://doi.org/10.1111/jgs.15346>.
- Bruce ML, Ten Have TR, Reynolds III CF, et al. Reducing suicidal ideation and depressive symptoms in depressed older primary care patients: a randomized controlled trial. *JAMA*. 2004;291(9):1081-1091. <https://doi.org/10.1001/jama.291.9.1081>.
- Buckner JD, Schmidt NB, Lang AR, Small JW, Schlauch RC, Lewinsohn PM. Specificity of social anxiety disorder as a risk factor for alcohol and cannabis dependence. *J Psychiatric Res*. 2008;42(3):230-239. <https://doi.org/10.1016/j.jpsychires.2007.01.002>.
- Budney, A. J., Moore, B. A., Vandrey, R. G., & Hughes, J. R. (2003). The time course and significance of cannabis withdrawal. *J Abnormal Psychol*, 112(3), 393-402. <https://doi.org/10.1037/0021-843X.112.3.393>.
- Bunka D, LeBras M, Oroz I. Topical Cannabis: Does It Live up to Its Presumed Pot Ential? RxFiles. <https://www.rxfiles.ca/rxfiles/uploads/documents/QandA-Topical%20Cannabis.pdf>. Published June 2019. Accessed September 15, 2021.
- Burggren AC, Siddarth P, Mahmood Z, et al. Subregional hippocampal thickness abnormalities in older adults with a history of heavy cannabis use. *Cannabis Cannabinoid Res*. 2018;3(1):242-251. Published December 8 2018. <https://doi.org/10.1089/can.2018.0035>.
- Busse JW, Vankrunkelsven P, Zeng L, et al. Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline. *BMJ*. 2021;374:n2040. <https://doi.org/10.1136/bmj.n2040>.
- Buying Cannabis in Manitoba. Liquor, Gaming and Cannabis Authority of Manitoba. <https://lgcamb.ca/cannabis/store-list/>. Accessed October 22, 2021.
- Canadian cannabis survey 2020: Summary. Government of Canada. <https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/research-data/canadian-cannabis-survey-2020-summary.html>. Published December 21, 2020.
- Canadian Cannabis Survey 2020: Summary. Government of Canada. <https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/research-data/canadian-cannabis-survey-2020-summary.html#a3>. Published December 21, 2020. Accessed September 15, 2021.
- Canadian Centre on Substance Use and Addiction. Clearing the smoke on cannabis: Regular use and mental health. <https://www.ccsa.ca/clearing-smoke-cannabis-regular-use-and-mental-health>. 2019.
- Canadian Centre on Substance Use and Addiction. Clearing the Smoke on Cannabis Highlights. <https://www.ccsa.ca/sites/default/files/2020-10/CCSA-Clearing-the-Smoke-on-Cannabis-Highlights-2020-en.pdf>. Updated August 2020.
- Canadian Coalition for Seniors' Mental Health. Needs assessment survey on cannabis and older adults. 2020. Available upon request: [info@ccsmh.ca](mailto:info@ccsmh.ca).
- Canadian Institute for Health Information. Drug Use Among Seniors in Canada, 2016. Ottawa, ON: CIHI; 2018. <https://www.cihi.ca/en/drug-use-among-seniors-in-canada>.
- Cannabasics Plant and Products. Canadian Public Health Association. <https://www.cpha.ca/sites/default/files/uploads/resources/cannabis/cannabasics-2018-plants-products-e.pdf>. Accessed August 16, 2021.
- Cannabinoids: Overview. Rxfiles. <https://www.rxfiles.ca/rxfiles/uploads/documents/Pain-QandA-cannabinoids.pdf>. Published 2021. Accessed December 16, 2021.
- Cannabis Act, SC 2018, c 16. <https://canlii.ca/t/543mn>. CanLII. Published 2018. Accessed October 6, 2021.
- Cannabis Basics: The Cannabis Plant. Ontario Cannabis Store. <https://ocs.ca/blogs/cannabis-anatomy/the-cannabis-plant>. Accessed August 17, 2021.
- Cannabis Regulations. SOR/2018-144 CanLII. <https://laws-lois.justice.gc.ca/PDF/SOR-2018-144.pdf>. Last amended on October 17, 2020. Accessed October 6, 2021.
- Cannabis Retail Seal. Alcohol and Gaming Commission of Ontario. <https://www.agco.ca/content/cannabis-retail-seal>. Accessed October 22, 2021.
- Cannabis Screening Tools. Canadian Public Health Association. <https://www.cpha.ca/cannabis-screening-tools>. Published 2016. Accessed January 4, 2022.
- Cannabis toolkit: A holistic approach to supporting healthy conversations about cannabis in First Nations communities. Thunderbird Partnership Foundation. <https://thunderbirdpf.org/new-cannabis-toolkit/>. Published September 6, 2019.

- Cannabis. Harm Reduction TO. <https://harmreductionto.ca/cannabis>. Accessed December 16, 2021.
- Cannabis: Inhaling vs Ingesting. Canadian Centre on Substance Use and Addiction. <https://www.ccsa.ca/sites/default/files/2019-10/CCSA-Cannabis-Inhaling-Ingesting-Risks-Infographic-2019-en.pdf>. Accessed September 15, 2021.
- Chang Y, Zhu M, Vannabouathong C, Mundi R, Chou RS, Bhandari M. Medical cannabis for chronic noncancer pain: A systematic review of health care recommendations. Enax-Krumova EK, ed. *Pain Res Manag.* 2021;2021:1-9. <https://doi.org/10.1155/2021/8857948>.
- Choi NG, Dinitto DM, Arndt S. Potential harms of marijuana use among older adults. *Public Pol Aging Report.* 2019;29(3):88-94. <https://doi.org/10.1093/ppar/prz011>.
- Choi NG, Marti CN, DiNitto DM, Choi BY. Older adults' marijuana use, injuries, and emergency department visits. *Am J Drug Alcohol Abuse.* 2018;44(2):215-223. <https://doi.org/10.1080/00952990.2017.1318891>
- Clearing the haze: How the legalization of recreational cannabis may affect your medical practice. Canadian Medical Protective Association. <https://www.cmpa-acpm.ca/en/advice-publications/browse-articles/2018/clearing-the-haze-how-the-legalization-of-recreational-marijuana-may-affect-your-medical-practice>. Revised 2020.
- CMA Policy: Authorizing Cannabis for Medical Purposes. Canadian Medical Association. <https://policybase.cma.ca/viewer?file=%2Fmedia%2FPolicyPDF%2FDPD15-04.pdf#page=1&search=Authorizing%20cannabis%20medical%20purposes&phrase=false>. Updated February 2020. Accessed October 6, 2021.
- Connor JP, Stjepanović D, Le Foll B, Hoch E, Budney AJ, Hall WD. Cannabis use and cannabis use disorder. *Nat Rev Dis Primers.* 2021;7(1):16. <https://doi.org/10.1038/s41572-021-00247-4>.
- Consultation on cannabis regulatory issues. Government of Canada. <https://www.canada.ca/en/health-canada/programs/consultation-cannabis-regulatory-issues.html>. Published December 11, 2020.
- Crawley A, LeBras M, Regler L, Jensen B. Cannabinoids: Comparison Chart. ©www.RxFiles.ca. [https://www.cfp.ca/content/cfp/suppl/2019/11/07/65.11.807.DC1/807\\_Cannabinoids\\_Comparison\\_Chart.pdf](https://www.cfp.ca/content/cfp/suppl/2019/11/07/65.11.807.DC1/807_Cannabinoids_Comparison_Chart.pdf). Updated November 2019. Accessed September 9, 2021.
- Cuttler C, Spradlin A, McLaughlin RJ. A naturalistic examination of the perceived effects of cannabis on negative affect. *J Affect Dis.* 2018;235:198-205. <https://doi.org/10.1016/j.jad.2018.04.054>.
- Danziger N, Bernstein N. Plant architecture manipulation increases cannabinoid standardization in "drug-type" medical cannabis. *Industrial Crops Products.* 2021;167:113528. <https://doi.org/10.1016/j.indcrop.2021.113528>.
- Derry S, Conaghan P, Da Silva JAP, Wiffen PJ, Moore RA. Topical NSAIDs for chronic musculoskeletal pain in adults. *Cochrane Database Syst Rev.* Published online April 22, 2016. <https://doi.org/10.1002/14651858.cd007400.pub3>.
- Desjardins J. The 6,000-Year History of Medical Cannabis. Visualcapitalist.com. Published 2018. <https://www.visualcapitalist.com/wp-content/uploads/2018/06/history-of-medical-cannabis.html>
- Desjardins J. The Anatomy of a Cannabis Plant, and its Lifecycle. Visual Capitalist. <https://www.visualcapitalist.com/anatomy-cannabis-plant/>. Published September 11, 2018.
- Di Forti M, Iyegbe C, Sallis H, et al. Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. *Biol Psychiatry.* 2012;72(10):811-816. <https://doi.org/10.1016/j.biopsych.2012.06.020>.
- Di Marzo V, Piscitelli F. The endocannabinoid system and its modulation by phytocannabinoids. *Neurotherapeutics.* 2015;12(4):692-698. <https://doi.org/10.1007/s13311-015-0374-6>.
- Diagnostic and Statistical Manual of Mental Disorders 5th ed. (DSM-5). Psychiatry Online - American Psychiatric Association. Washington D.C. Substance-Related and Addictive Disorders. <https://doi.org/10.1176/appi.books.9780890425596.dsm16>. c2013. Accessed December 20, 2021.
- EDN54 General Overview of the Cannabis Excise Stamps. Canada Revenue Agency, Government of Canada. <https://www.canada.ca/en/revenue-agency/services/forms-publications/publications/edn54.html>. Published May 2018. Accessed October 22, 2021.
- Ee C, Lake J, Firth J, et al. An integrative collaborative care model for people with mental illness and physical comorbidities. *Int J Ment Health Syst.* 2020;14(article number 83). <https://doi.org/10.1186/s13033-020-00410-6>.
- Fagan SG, Campbell VA. The influence of cannabinoids on generic traits of neurodegeneration. *Brit J Pharmacology.* 2014;171(6):1347-1360. <https://doi.org/10.1111/bph.12492>.
- Farnsworth NR. Pharmacognosy and chemistry of 'cannabis sativa'. *J Am Pharmaceut Assoc* (1961). 1969;9(8):410-440. [https://doi.org/10.1016/s0003-0465\(16\)30933-8](https://doi.org/10.1016/s0003-0465(16)30933-8).
- Finn DP, Haroutounian S, Hohmann AG, Krane E, Soliman N, Rice AS. Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies. *Pain.* 2021;162:S5-S25. <https://doi.org/10.1097/j.pain.0000000000002268>.
- Fischer B, Russell C, Sabioni P, et al. Lower-Risk Cannabis Use Guidelines (LRCUG): An evidence-based update. *AJPH.* 2017;107(8):e1-e12. <https://doi.org/10.2105/AJPH.2017.303818>.
- Gabrys R. Clearing the Smoke on Cannabis: Edible Cannabis Products, Cannabis Extracts and Cannabis Topicals. Canadian Centre on Substance Use and Addiction. <https://ccsa.ca/sites/default/files/2020-05/CCSA-Edible-Cannabis-Extracts-and-Topicals-Report-2020-en.pdf>. 2020.
- Gale RT. What are some of the chemicals in cannabis sativa? Michael G. DeGroot Centre for Medicinal Cannabis Research. <https://cannabisresearch.mcmaster.ca/news/2017/11/01/a-new-trove-of-pharmaceuticals-the-vast-repertoire-of-phytochemicals-in-cannabis-sativa>. Published November 1, 2017. Accessed June 30, 2021.
- Goodrich DE, Kilbourne AM, Nord KM, Bauer MS. Mental health collaborative care and its role in primary care settings. *Curr Psychiatry Rep.* 2013;15(8):383. <https://doi.org/10.1007/s11920-013-0383-2>.
- Grinspoon P. Medical marijuana. Harvard Health Blog. <https://www.health.harvard.edu/blog/medical-marijuana-2018011513085>. Harvard Health Publishing. Published January 9, 2018. Updated April 10, 2020.
- Groenkaer M, de Crespigny C, Liu D, et al. "The Chicken or the egg": Barriers and facilitators to collaborative care for people with comorbidity in a metropolitan region of South Australia. *Issues Mental Health Nurs.* 2017;38(1):18-24. [published first online October 14, 2016]. <https://doi.org/10.1080/01612840.2016.1233596>.
- Guilloard M, Authier N, Pereira B, Soubrier M, Mathieu S. Cannabis use assessment and its impact on pain in rheumatologic diseases: a systematic review and meta-analysis. *Rheumatology.* 2021;60(2):549-556. <https://doi.org/10.1093/rheumatology/keaa534>.
- GW Pharma Ltd. Product Monograph PRSATIVE® delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) Solution, 27 mg/mL / 25 mg/mL, Buccal spray. <https://www.bayer.com/sites/default/files/2020-11/sativex-pm-en.pdf>. Histon, Cambridge UK; 2005. Date of Revision: December 11, 2019.
- Hall W, Stjepanović D, Caulkins J, et al. Public health implications of legalising the production and sale of cannabis for medicinal and recreational use. *The Lancet.* 2019;394(10208):1580-1590. [https://doi.org/10.1016/s0140-6736\(19\)31789-1](https://doi.org/10.1016/s0140-6736(19)31789-1).
- Harm Reduction. Harm Reduction TO. <https://harmreductionto.ca/what-is-harm-reduction>. Accessed December 16, 2021.
- Hassell C, Wilkins K, Trevisan LA. Pharmacology of geriatric substance use disorders: Considerations and future directions. *Curr Treatment Options Psychiat.* 2017;4(1):102-115. <https://doi.org/10.1007/s40501-017-0107-z>.
- Hazekamp A, Fischechick JT. Cannabis – from cultivar to chemovar. *Drug Testing Analysis.* 2012;4(7-8):660-667. <https://doi.org/10.1002/dta.407>.
- Health Product InfoWatch, January 2020. Government of Canada. <https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/health-product-infowatch/january-2020.html#a4.1>. Published January 30, 2020. Accessed September 15, 2021.
- Herrmann N, Ruthirakuhan M, Gallagher D, et al. Randomized placebo-controlled trial of nabilone for agitation in Alzheimer's Disease. *Am J Geriatr Psychiatry.* 2019;27(11):1161-1173. <https://doi.org/10.1016/j.jagp.2019.05.002>.
- Hindocha C, Cousijn J, Rall M, Bloomfield MAP. The effectiveness of cannabinoids in the treatment of posttraumatic stress disorder (PTSD): A systematic review. *J Dual Diagn.* 2019[online];16(1):120-139. <https://doi.org/10.1080/15504263.2019.1652380>
- History.com Editors. Marijuana. HISTORY. <https://www.history.com/topics/crime/history-of-marijuana>. Updated October 10, 2019.
- Information for health care professionals: Cannabis (marihuana, marijuana) and the cannabinoids. Government of Canada. <https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/information-medical-practitioners/information-health-care-professionals-cannabis-cannabinoids.html>. Published 2018.
- Interprofessional Comprehensive Geriatric Toolkit. Created by the South West (Ontario) Assess and Restore project team. <https://cgatoolkit.ca/>. Accessed November 22, 2021.
- Introduction to the Canadian Coalition for Seniors' Mental Health (CCSMH) Guidelines on Substance Use Disorders Among Older Adults. Canadian Coalition for Seniors' Mental Health. [https://ccsmh.ca/wp-content/uploads/2019/12/Canadian\\_Guidelines\\_Introduction\\_Doc\\_ENG.pdf](https://ccsmh.ca/wp-content/uploads/2019/12/Canadian_Guidelines_Introduction_Doc_ENG.pdf). Published 2019. Accessed December 16, 2021.
- Is there a link between marijuana use and psychiatric disorders? National Institute on Drug Abuse. <https://www.drugabuse.gov/publications/research-reports/marijuana/there-link-between-marijuana-use-psychiatric-disorders>. Revised July 2020.
- Jetly R, Heber A, Fraser G, Boisvert D. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study. *Psychoneuroendocrinology.* 2015;51:585-588. <https://doi.org/10.1016/j.psyneuen.2014.11.002>.
- Jiggins, J. (N.D). True Hemp in Australia. October 11, 2010.
- Kalant H, Porath-Waller AJ. Clearing the Smoke on Cannabis: Medical Use of Cannabis and Cannabinoids – An Update. Canadian Centre on Substance Use and Addiction <https://www.ccsa.ca/sites/default/files/2019-04/CCSA-Medical-Use-of-Cannabis-Report-2016-en.pdf>. Published 2016. Accessed December 23, 2021.
- Kuerbis A, Sacco P, Blazer DG, Moore AA. Substance abuse among older adults. *Clin Geriatr Med.* 2014;30(3):629-654. <https://doi.org/10.1016/j.cger.2014.04.008>.
- Kum V, Bell A, Fang W, VanWert E. Efficacy of topical capsaicin for cannabinoid hyperemesis syndrome in a pediatric and adult emergency department. *Am J Emerg Med.* 2021;49:343-351. <https://doi.org/10.1016/j.ajem.2021.06.049>.
- Lee C, Lin M, Martins KJB, et al. Opioid use in medical cannabis authorization adult patients from 2013 to 2018: Alberta, Canada. *BMC Public Health.* 2021;21(article number 843). <https://doi.org/10.1186/s12889-021-10867-w>.



- Lee C, Round JM, Klarenbach S, et al. Gaps in evidence for the use of medically authorized cannabis: Ontario and Alberta, Canada. *Harm Reduct J*. 2021;18(Article number 61). <https://doi.org/10.1186/s12954-021-00509-0>.
- Li H. An archaeological and historical account of cannabis in China. *Econ Bot*. 1973;28(4):437-448. <https://doi.org/10.1007/bf02862859>.
- Lovell ME, Akhurst J, Padgett C, Garry MI, Matthews A. Cognitive outcomes associated with long-term, regular, recreational cannabis use in adults: A meta-analysis. *Experim Clin Psychopharmacology*. 2020;28(4):471-494. Published online October 31, 2019. <https://doi.org/10.1007/s00406-018-0970-7>.
- Lovell ME, Bruno R, Johnston J, et al. Cognitive, physical, and mental health outcomes between long-term cannabis and tobacco users. *Addict Behav*. 2018;79:178-188. <https://doi.org/10.1016/j.addbeh.2017.12.009>.
- Lowe DJE, Sasiadek JD, Coles AS, George TP. Cannabis and mental illness: a review. *Eur Arch Psychiatry Clin Neurosci*. 2019;269:107-120. <https://doi.org/10.1007/s00406-018-0970-7>.
- Lucas P, Boyd S, Milloy MJ, Walsh Z. Reductions in alcohol use following medical cannabis initiation: results from a large cross-sectional survey of medical cannabis patients in Canada [published online ahead of print, 2020 Oct 15]. *Int J Drug Policy*. 2020;86:102963. <https://doi.org/10.1016/j.drugpo.2020.102963>.
- MacCallum CA, Eadie L, Barr AM, Boivin M, Lu S. Practical strategies using medical cannabis to reduce harms associated with long term opioid use in chronic pain. *Front Pharmacol*. 2021;12:633168. <https://doi.org/10.3389/fphar.2021.633168>.
- MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. *Eur J Internal Med*. 2018;49:12-19. <https://doi.org/10.1016/j.ejim.2018.01.004>.
- Manning L, Bouchard L. Medical cannabis use: Exploring the perceptions and experiences of older adults with chronic conditions. *Clin Gerontol*. 2021;44:1:32-41. <https://doi.org/10.1080/07317115.2020.1853299>.
- Marijuana Research: About. The Marijuana Project. The University of Mississippi. <https://pharmacy.olemiss.edu/marijuana/about/>. Accessed August 17, 2021.
- Marshall K, Gowing L, Ali R, Le Foll B. Pharmacotherapies for cannabis dependence. *Cochrane Database Syst Rev*. 2014;12(12):CD008940. <https://doi.org/10.1002/14651858.CD008940.pub2>.
- McClements DJ. Enhancing efficacy, performance, and reliability of cannabis edibles: Insights from lipid bioavailability studies. *Annu Rev Food Sci Technol*. 2020;11(1):45-70. <https://doi.org/10.1146/annurev-food-032519-051834>.
- Medical Cannabinoids: Guideline Summary. College of Family Physicians of Canada [https://www.cfpc.ca/CFPC/media/Resources/Addiction-Medicine/Cannabinoid-Guidelines\\_One-Pager.pdf](https://www.cfpc.ca/CFPC/media/Resources/Addiction-Medicine/Cannabinoid-Guidelines_One-Pager.pdf).
- Medical Cannabis. Canadian Pharmacists Association. <https://www.pharmacists.ca/advocacy/issues/medical-cannabis/>. Accessed October 25, 2021.
- Miele GM, Carpenter KM, Cockerham MS, Trautman KD, Blaine J, Hasin DS. Concurrent and predictive validity of the Substance Dependence Severity Scale (SDSS). *Drug and Alcohol Depend*. 2000;59(1):77-88. [https://doi.org/10.1016/s0376-8716\(99\)00110-6](https://doi.org/10.1016/s0376-8716(99)00110-6).
- Mikuriya TH. Marijuana in medicine: past, present and future. *Calif Med*. 1969;110(1):34-40.
- Minerbi A, Häuser W, Fitzcharles M-A. Medical cannabis for older patients. *Drugs & Aging*. 2018;36:39-51. <https://doi.org/10.1007/s40266-018-0616-5>.
- Mok J, Milloy MJ, Grant C, et al. Use of cannabis for harm reduction among people at high risk for overdose in Vancouver, Canada (2016–2018). *AJPH*. 2021;111(5):969-972. <https://doi.org/10.2105/AJPH.2021.306168>.
- More SV, Choi D-K. Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection. *Molecular Neurodegeneration*. 2015;10(Article number 17). <https://doi.org/10.1186/s13024-015-0012-0>.
- Nabilone: Drug information. Access Lexicomp Online for additional drug information, tools, and databases. Hudson, OH: Lexicomp, 2021. [https://www.uptodate.com/contents/nabilone-drug-information?search=nabilone&source=panel\\_search\\_result&selectedTitle=1~19&usage\\_type=panel&kp\\_tab=drug\\_general&display\\_rank=1](https://www.uptodate.com/contents/nabilone-drug-information?search=nabilone&source=panel_search_result&selectedTitle=1~19&usage_type=panel&kp_tab=drug_general&display_rank=1)
- Nabiximols: Drug information. Access Lexicomp Online for additional drug information, tools, and databases. Hudson, OH: Lexicomp, 2021. [https://www.uptodate.com/contents/nabiximols-united-states-not-available-drug-information?search=nabiximols&source=panel\\_search\\_result&selectedTitle=1~15&usage\\_type=panel&kp\\_tab=drug\\_general&display\\_rank=1](https://www.uptodate.com/contents/nabiximols-united-states-not-available-drug-information?search=nabiximols&source=panel_search_result&selectedTitle=1~15&usage_type=panel&kp_tab=drug_general&display_rank=1)
- National Academies of Sciences, Engineering, and Medicine. 2017. *The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research*. Washington, DC: The National Academies Press. <https://doi.org/10.17226/24625>.
- National Cannabis Survey: Detailed information for fourth quarter 2019. Statistics Canada. <https://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&id=1258630>. Accessed July 19, 2021.
- National Institute on Aging. Talking with Your Older Patient: A Clinician's Handbook. <https://order.nia.nih.gov/sites/default/files/2020-12/talking-with-older-patient.pdf>. Published February 2016. Accessed August 24, 2021.
- NICE rejects MS symptom-relieving treatments. MIMS. <https://www.mims.co.uk/nice-rejects-ms-symptom-relieving-treatments/neurology/article/1323758>. Accessed September 15, 2021.
- NSLC Cannabis. Nova Scotia Liquor Corporation. <https://cannabis.mynslc.com/en>. Accessed October 22, 2021.
- Nugent SM, Meghani SH, Rogal SS, Merlin JS. Medical cannabis use among individuals with cancer: An unresolved and timely issue. *Cancer*. 2020;126(9):1832-1836. <https://doi.org/10.1002/cncr.32732>.
- Okusanya BO, Asaolu IO, Ehiri JE, Kimaru LJ, Okechukwu A, Rosales C. Medical cannabis for the reduction of opioid dosage in the treatment of non-cancer chronic pain: a systematic review. *Syst Rev*. 2020;9:167. <https://doi.org/10.1186/s13643-020-01425-3>.
- Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. *Pharmacol Rev*. 2006;58(3):389-462. <https://doi.org/10.1124/pr.58.3.2>.
- Packaging and Labelling Guide for Cannabis Products. Government of Canada. [https://www.canada.ca/content/dam/hc-sc/documents/services/cannabis-regulations-licensed-producers/packaging-labelling-guide-cannabis-products/CURRENT\\_PUBLISHED\\_Packaging\\_and\\_labelling\\_guide\\_for\\_cannabis\\_products.PDF](https://www.canada.ca/content/dam/hc-sc/documents/services/cannabis-regulations-licensed-producers/packaging-labelling-guide-cannabis-products/CURRENT_PUBLISHED_Packaging_and_labelling_guide_for_cannabis_products.PDF). Published August 30, 2019. Accessed September 23, 2021.
- Pandey P, Irulappan V, Bagavathiannan MV, Senthil-Kumar M. Impact of combined abiotic and biotic stresses on plant growth and avenues for crop improvement by exploiting physio-morphological traits. *Front Plant Sci*. 2017;8:537. Published 2017 Apr 18. <https://doi.org/10.3389/fpls.2017.00537>.
- Parliament of Canada. *Bill C-45: An Act respecting cannabis and to amend the Controlled Drugs and Substance Act, the Criminal Code and other Acts*. Parliament of Canada. <https://www.parl.ca/DocumentViewer/en/42-1/bill/c-45/royal-assent>. Published June 21, 2018. Accessed June 3, 2021.
- PEI Cannabis. PEI Cannabis Corp. <https://peicannabiscorp.com/>. Accessed October 22, 2021.
- Pierre MS, Matthews L, Walsh Z. Cannabis education needs assessment among Canadian physicians-in-training. *Complement Therap Med*. 2020;49:102328. <https://doi.org/10.1016/j.ctim.2020.102328>.
- Policy and Regulations (Cannabis). Canadian Centre on Substance Use and Addiction. <https://www.ccsa.ca/policy-and-regulations-cannabis>. Accessed July 13, 2021.
- Product Monograph N Cesamet® Nabilone Capsules; 1mg, 0.5 mg, 0.25 mg. Valeant Canada limitée/Limited. Montreal, Quebec. <https://pdf.hres.ca/dpdp/00007760.PDF>. Revised March 17, 2009.
- Produits. SQDC (Societe quebecoise du cannabis). <https://www.sqdc.ca/fr-CA/produits>. Published 2021. Accessed October 22, 2021.
- Purcell C, Davis A, Moolman N, Taylor SM. Reduction of benzodiazepine use in patients prescribed medical cannabis. *Cannabis Cannabinoid Res*. 2019;4(3):214-218. <https://doi.org/10.1089/can.2018.0020>.
- Richards JR, Gordon BK, Danielson AR, Moulin AK. Pharmacologic treatment of cannabinoid hyperemesis syndrome: A systematic review. *Pharmacotherapy: J Human Pharmacol Drug Therapy*. 2017;37(6):725-734. <https://doi.org/10.1002/phar.1931>.
- Robbins, S. A green gold rush: potent marijuana big business for Colombia traffickers. openDemocracy. <https://www.opendemocracy.net/en/democraciabierta/febre-del-oro-verde-marihuana-creepy-beneficia-a-trafficantes-de-colombia-en/>. Published August 13, 2019. Accessed August 17, 2021.
- Roberts S. Integrating the medical and cannabis systems: A mock case study. *Can Pharm J*. 2020;153(2):74-75. <https://doi.org/10.1177/1715163520904986>.
- Russo E. Cognoscenti of cannabis I. *J Cannabis Therapeutics*. 2001;1(1):85-88. [https://doi.org/10.1300/j175v01n01\\_07](https://doi.org/10.1300/j175v01n01_07).
- Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *Br J Pharmacol*. 2011;163(7):1344-1364. <https://doi.org/10.1111/j.1476-5381.2011.01238.x>.
- Russo EB. The pharmacological history of cannabis. In: Pertwee R, ed. *Handbook of Cannabis*. UK: Oxford University Press; c2014. <https://oxford.universitypressscholarship.com/view/10.1093/acprof:oso/9780199662685.001.0001/acprof-9780199662685-chapter-2>. Accessed July 12, 2021. <https://doi.org/10.1093/acprof:oso/9780199662685.001.0001>.
- Sarkar S, Parmar A, Chatterjee B. Substance use disorders in the elderly: A review. *J Geriatr Mental Health*. 2015;2(2):74-82. <https://doi.org/10.4103/2348-9995.174271>.
- Sarkar, S., Parmar, A., & Chatterjee, B. (2015) Substance Use and Successful Aging: Key Issues and Considerations. In Substance use in Canada: improving quality of life: substance use and aging. Retrieved from: <https://www.ccsa.ca/sites/default/files/2019-04/CCSA-Substance-Use-and-Aging-Report-2018-en.pdf>
- Schultes RE. "Nectar of Delight." *Plants of the Gods – Their Sacred, Healing and Hallucinogenic Powers*. Vermont: Healing Arts Press; c1992:8. <https://www.worldcat.org/title/plants-of-the-gods-their-sacred-healing-and-hallucinogenic-powers/oclc/47666585>
- Screening, Brief Intervention, and Referral to Treatment (SBIRT). Substance Abuse and Mental Health Services Administration. <https://www.samhsa.gov/sbirt>. Updated 2021. Accessed December 16, 2021.
- Scully C. Cannabis; adverse effects from an oromucosal spray. *BDJ*. 2007;203(6):E12. <https://doi.org/10.1038/bdj.2007.749>.
- Shahbazi F, Grandi V, Banerjee A, Trant JF. Cannabinoids and cannabinoid receptors: The story so far. *iScience*. 2020;23(7):101301. <https://doi.org/10.1016/j.isci.2020.101301>.
- Sherman BJ, McRae-Clark AL. Treatment of cannabis use disorder: Current science and future outlook. *Pharmacotherapy*. 2016;36(5):511-535. <https://doi.org/10.1002/phar.1747>.
- Sholl L. The History of The Rastafari Movement and Cannabis. Royal Queen Seeds. <https://www.royalqueenseeds.com/blog-the-history-of-the-rastafari-movement-and-cannabis-n1018>. Published October 9, 2018.
- Sidhu, A. Medical Cannabis Use in the Older Adult. McMaster University. PowerPoint Presentation: <https://www.rgpeo.com/wp-content/uploads/2018/03/sidhu-a-medical-cannabis-in-elderly.pdf>.

- Smith LA, Azariah F, Lavender VT, Stoner NS, Bettiol S. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. *Cochrane Database Syst Rev*. Published online November 12, 2015. <https://doi.org/10.1002/14651858.cd009464.pub2>.
- Socias ME, Choi J, Lake S, et al. Cannabis use is associated with reduced risk of exposure to fentanyl among people on opioid agonist therapy during a community-wide overdose crisis [published correction appears in *Drug Alcohol Depend*. 2021 Apr 1;221:108547. <https://doi.org/10.1016/j.drugalcdep.2021.108547>]. *Drug Alcohol Depend*. 2021;219:108420. <https://doi.org/10.1016/j.drugalcdep.2020.108420>
- Statistics Canada. National cannabis survey, third quarter 2019. *The Daily*. <https://www150.statcan.gc.ca/n1/daily-quotidien/191030/dq191030a-eng.htm>. Published October 30th, 2019. Accessed August 10, 2021.
- Suraev AS, Marshall NS, Vandrey R, et al. Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies. *Sleep Med Rev*. 2020;53:101339. <https://doi.org/10.1016/j.smrv.2020.101339>.
- Sznitman S, Mabouk C, Said Z, Vulfsons S. Opioid and healthcare service use in medical cannabis patients with chronic pain: a prospective study. *BMJ Support Palliat Care*. Published Online First: 14 September 2021. <https://doi.org/10.1136/bmjspcare-2020-002661>.
- Sznitman SR, Vulfsons S, Meiri D, Weinstein G. Medical cannabis and cognitive performance in middle to old adults treated for chronic pain. *Drug Alc Rev*. 2020;40(2):272-280. Published online September 22, 2020. <https://doi.org/10.1111/dar.13171>.
- Talking Cannabis. Western Health (Newfoundland and Labrador). [https://westernhealth.nl.ca/uploads/Addictions%20Prevention%20and%20Mental%20Health%20Promotion/Talking%20Cannabis%20Key%20Messages%202019\\_.pdf](https://westernhealth.nl.ca/uploads/Addictions%20Prevention%20and%20Mental%20Health%20Promotion/Talking%20Cannabis%20Key%20Messages%202019_.pdf). Published 2019. Accessed August 11, 2021.
- The College of Family Physicians of Canada. Guidance in Authorizing Cannabis Products within Primary Care. <https://www.cfpc.ca/CFPC/media/PDF/CFPC-Guidance-in-Cannabis-Within-Primary-Care.pdf>. March 2021. Accessed September 9, 2021.
- Thomas PA, Carter GT, Bombardier CH. A scoping review on the effect of cannabis on pain intensity in people with spinal cord injury. *J Spinal Cord Med*. Published online January 19, 2021;1-12. <https://doi.org/10.1080/10790268.2020.1865709>.
- Touw M. The religious and medicinal uses of Cannabis in China, India and Tibet. *J Psychoactive Drugs*. 1981;13(1):23-34. <https://doi.org/10.1080/02791072.1981.10471447>.
- Tracy K, Wallace SP. Benefits of peer support groups in the treatment of addiction. *Subst Abuse Rehabil*. 2016;7:143-154. <https://doi.org/10.2147/SAR.S81535>.
- Tramer MR. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. *BMJ*. 2001;323(7303):16. <https://doi.org/10.1136/bmj.323.7303.16>.
- Turna J, Patterson B, Van Ameringen M. Is cannabis treatment for anxiety, mood, and related disorders ready for prime time? *Depression & Anxiety*. 2017;34(11):1006-1017. <https://doi.org/10.1002/da.22664>.
- UN Commission on Narcotic Drugs reclassifies cannabis to recognize its therapeutic uses. World Health Organization. <https://www.who.int/news/item/04-12-2020-un-commission-on-narcotic-drugs-reclassifies-cannabis-to-recognize-its-therapeutic-uses>. Accessed February 16, 2021.
- Unützer J, Katon W, Callahan CM, et al. Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. *JAMA*. 2002;288(22):2836-2845. <https://doi.org/10.1001/jama.288.22.2836>
- van den Elsen GA, Ahmed AI, Lammers M, et al. Efficacy and safety of medical cannabinoids in older subjects: a systematic review. *Ageing Res Rev*. 2014;14:56-64. <https://doi.org/10.1016/j.arr.2014.01.007>.
- van der Pol P, Liebrechts N, de Graaf R, Korff DJ, van den Brink W, van Laar M. Predicting the transition from frequent cannabis use to cannabis dependence: a three-year prospective study. *Drug Alcohol Depend*. 2013;133(2):352-359. <https://doi.org/10.1016/j.drugalcdep.2013.06.009>.
- van der Pol P, Liebrechts N, de Graaf R, Korff DJ, van den Brink W, van Laar M. Reliability and validity of the Severity of Dependence Scale for detecting cannabis dependence in frequent cannabis users. *Int J Methods Psychiatr Res*. 2013;22(2):138-143. <https://doi.org/10.1002/mpr.1385>. Published online May 14, 2013.
- Wade DT, Collin C, Stott C, Duncombe P. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. *Mult Scler J*. 2010;16(6):707-714. <https://doi.org/10.1177/1352458510367462>
- Warf B. High points: An historical geography of cannabis. *Geographical Rev*. 2014;104(4):414-438. <https://doi.org/10.1111/j.1931-0846.2014.12038.x>.
- Werneck MA, Kortas GT, de Andrade AG, Castaldelli-Maia JM. A systematic review of the efficacy of cannabinoid agonist replacement therapy for cannabis withdrawal symptoms. *CNS Drugs*. 2018;32(12):1113-1129. <https://doi.org/10.1007/s40263-018-0577-6>.
- What counts as one drink? Addiction Technology Transfer Centre Network. <https://www.sbirdt.care/pdfs/tools/Hard%20Card%20August%202016.PDF>. Published June 2016. Accessed December 16, 2021.
- Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. *JAMA*. 2015;313(24):2456-2473. <https://doi.org/10.1001/jama.2015.6358>.
- Wolfe D, Corace K, Rice D, et al. Effects of medical and non-medical cannabis use in older adults: protocol for a scoping review. *BMJ Open*. 2020;10(2):e034301. <https://doi.org/10.1136/bmjopen-2019-034301>.
- Workman CD, Fietsam AC, Sosnof J, Rudroff T. Increased likelihood of falling in older cannabis users vs. non-users. *Brain Sci*. 2021;11(2):134. <https://doi.org/10.3390/brainsci11020134>.
- Workplace Strategies: Risk of Impairment from Cannabis, 3rd Edition. Canadian Centre for Occupational Health and Safety (CCOHS). [https://www.ccohs.ca/products/publications/cannabis\\_whitepaper.pdf](https://www.ccohs.ca/products/publications/cannabis_whitepaper.pdf). 2018.
- Yen PH, Leasure AR. Use and effectiveness of the teach-back method in patient education and health outcomes. *Fed Pract*. 2019;36(6):284-289. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590951/>.
- Ziemianski D, Capler R, Tekanoff R, Lacasse A, Luconi F, Ware MA. Cannabis in medicine: a national educational needs assessment among Canadian physicians. *BMC Med Educ*. 2015;15:52. <https://doi.org/10.1186/s12909-015-0335-0>.
- Zloczower O, Brill S, Zeitak Y, Peles E. Risk and benefit of cannabis prescription for chronic non-cancer pain. [Published online ahead of print, 2021 Aug 2]. *J Addict Dis*. 2021;1-11. <https://doi.org/10.1080/10550887.2021.1956673>.